PDL BIOPHARMA, INC. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 11, 2020

Attached files

file filename
EX-4.8 - DESCRIPTION OF REGISTRANTS SECURITIES - PDL BIOPHARMA, INC.pdli1231201910-kex48.htm
EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC.pdli1231201910-kex321.htm
EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC.pdli1231201910-kex312.htm
EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC.pdli1231201910-kex311.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - PDL BIOPHARMA, INC.pdli1231201910-kex211.htm
EX-10.76 - WIND DOWN RETENTION PLAN - PDL BIOPHARMA, INC.pdli1231201910-kex1076.htm
EX-10.75 - FORM OF INDUCEMENT RESTRICTED STOCK AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1075.htm
EX-10.74 - FORM OF NONSTATUTORY INDUCMENT STOCK OPTION AGREEMENT NOTICE SUPPPLEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1074.htm
EX-10.73 - FORM OF NONSTATUTORY INDUCMENT STOCK OPTION AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1073.htm
EX-10.72 - FORM OF STOCK OPTION GRANT NOTICE SUPPLEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1072.htm
EX-10.71 - FORM OF STOCK OPTION AGREEMENT AMENDMENT ACKNOWLEDGEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1071.htm
EX-10.70 - FORM OF STOCK OPTION AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1070.htm
EX-10.69 - FORM OF RESTRICTED STOCK AGREEMENT AMENDMENT ACKNOWLEDGEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1069.htm
EX-10.68 - FORM OF RESTRICTED STOCK AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1068.htm
EX-10.67 - SEVERANCE PLAN - PDL BIOPHARMA, INC.pdli1231201910-kex1067.htm
EX-10.66 - FIFTH AMENDEMENT TO LEASE AGREEMENT - PDL BIOPHARMA, INC.pdli1231201910-kex1066.htm
10-K - 10-K - PDL BIOPHARMA, INC.pdli1231201910-kdoc.htm


Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-36708, 333-122760, 333-123958, 333-128644, 333-211970 and 333-231870) and on Form S-8 (No. 333-87957, 333-68314, 333-104170, 333-125906, 333-145262, 333-220370, 333-220435 and 333-225534) of PDL Biopharma, Inc., of our report dated March 11, 2020 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
 

/s/ PricewaterhouseCoopers LLP
San Francisco, California
March 11, 2020



PDL BIOPHARMA, INC. Reports